Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data

To compare clinical trial results for crizotinib and entrectinib in -positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. We analyzed four phase I-II studies using a simulated treatment comparison (STC). A STC of clinical trial versus real-world...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2022-06, Vol.18 (17), p.2063-2074
Main Authors: Tremblay, Gabriel, Groff, Michael, Iadeluca, Laura, Daniele, Patrick, Wilner, Keith, Wiltshire, Robin, Bartolome, Lauren, Usari, Tiziana, Cappelleri, Joseph C, Camidge, D Ross
Format: Article
Language:English
Subjects:
Benzamides - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Clinical Trials as Topic
Crizotinib - therapeutic use
Humans
Indazoles - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - genetics
Protein-Tyrosine Kinases - therapeutic use
Proto-Oncogene Proteins - genetics
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c332t-fd581923528b6539c462ac336a3639ac1e508e955ff349089e6c7d276b74d2f83
cites cdi_FETCH-LOGICAL-c332t-fd581923528b6539c462ac336a3639ac1e508e955ff349089e6c7d276b74d2f83
container_end_page 2074
container_issue 17
container_start_page 2063
container_title Future oncology (London, England)
container_volume 18
creator Tremblay, Gabriel
Groff, Michael
Iadeluca, Laura
Daniele, Patrick
Wilner, Keith
Wiltshire, Robin
Bartolome, Lauren
Usari, Tiziana
Cappelleri, Joseph C
Camidge, D Ross
description To compare clinical trial results for crizotinib and entrectinib in -positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. We analyzed four phase I-II studies using a simulated treatment comparison (STC). A STC of clinical trial versus real-world evidence compared crizotinib clinical data to real-world outcomes. Adjusted STC found nonsignificant trends favoring crizotinib over entrectinib: objective response rate, risk ratio = 1.04 (95% CI: 0.85-1.28); median duration of response, mean difference = 16.11 months (95% CI: -1.57- 33.69); median progression-free survival, mean difference = 3.99 months (95% CI: -6.27-14.25); 12-month overall survival, risk ratio = 1.01 (95% CI: 0.90-1.12). Nonsignificant differences were observed between the trial end point values and the real-world evidence for crizotinib. Crizotinib and entrectinib have comparable efficacy in -positive non-small-cell lung cancer.
doi_str_mv 10.2217/fon-2021-1102
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2635239057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2635239057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c332t-fd581923528b6539c462ac336a3639ac1e508e955ff349089e6c7d276b74d2f83</originalsourceid><addsrcrecordid>eNo9kMtPxCAQh4nRuLp69Go4ekF5FFqOZrM-kk028XFuKAWDoXSFdo0e_Nst2dUTw8w3k18-AC4IvqaUlDe2D4hiShAhmB6AE1IWBaoYJodTXZQSCSGLGThN6R3jomQcH4MZ45RRyvAJ-Flaa_TgtiaYlGBvoY7uux9ccA3cmpjGBE0YYmZyywX4tH4mEG365PIaDFOA1CnvkTbeQz-GN6hV0CbCMbn88dOmVh6q0MJolEefffQtbNWgzsCRVT6Z8_07B693y5fFA1qt7x8XtyukGaMDsi2viKRT7KoRnEldCKqmkVBMMKk0MRxXRnJuLSskrqQRumxpKZqyaKmt2Bxc7e5uYv8xmjTUnUs5rwqmH1NNRVYiMS8nFO1QHfuUorH1JrpOxa-a4DorryfldVZeZ-UTf7k_PTadaf_pP8fsF-qjfTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2635239057</pqid></control><display><type>article</type><title>Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data</title><source>PubMed Central</source><creator>Tremblay, Gabriel ; Groff, Michael ; Iadeluca, Laura ; Daniele, Patrick ; Wilner, Keith ; Wiltshire, Robin ; Bartolome, Lauren ; Usari, Tiziana ; Cappelleri, Joseph C ; Camidge, D Ross</creator><creatorcontrib>Tremblay, Gabriel ; Groff, Michael ; Iadeluca, Laura ; Daniele, Patrick ; Wilner, Keith ; Wiltshire, Robin ; Bartolome, Lauren ; Usari, Tiziana ; Cappelleri, Joseph C ; Camidge, D Ross</creatorcontrib><description>To compare clinical trial results for crizotinib and entrectinib in -positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. We analyzed four phase I-II studies using a simulated treatment comparison (STC). A STC of clinical trial versus real-world evidence compared crizotinib clinical data to real-world outcomes. Adjusted STC found nonsignificant trends favoring crizotinib over entrectinib: objective response rate, risk ratio = 1.04 (95% CI: 0.85-1.28); median duration of response, mean difference = 16.11 months (95% CI: -1.57- 33.69); median progression-free survival, mean difference = 3.99 months (95% CI: -6.27-14.25); 12-month overall survival, risk ratio = 1.01 (95% CI: 0.90-1.12). Nonsignificant differences were observed between the trial end point values and the real-world evidence for crizotinib. Crizotinib and entrectinib have comparable efficacy in -positive non-small-cell lung cancer.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2021-1102</identifier><identifier>PMID: 35232230</identifier><language>eng</language><publisher>England</publisher><subject>Benzamides - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Clinical Trials as Topic ; Crizotinib - therapeutic use ; Humans ; Indazoles - therapeutic use ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Protein Kinase Inhibitors - therapeutic use ; Protein-Tyrosine Kinases - genetics ; Protein-Tyrosine Kinases - therapeutic use ; Proto-Oncogene Proteins - genetics ; Treatment Outcome</subject><ispartof>Future oncology (London, England), 2022-06, Vol.18 (17), p.2063-2074</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c332t-fd581923528b6539c462ac336a3639ac1e508e955ff349089e6c7d276b74d2f83</citedby><cites>FETCH-LOGICAL-c332t-fd581923528b6539c462ac336a3639ac1e508e955ff349089e6c7d276b74d2f83</cites><orcidid>0000-0003-0623-3545</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35232230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tremblay, Gabriel</creatorcontrib><creatorcontrib>Groff, Michael</creatorcontrib><creatorcontrib>Iadeluca, Laura</creatorcontrib><creatorcontrib>Daniele, Patrick</creatorcontrib><creatorcontrib>Wilner, Keith</creatorcontrib><creatorcontrib>Wiltshire, Robin</creatorcontrib><creatorcontrib>Bartolome, Lauren</creatorcontrib><creatorcontrib>Usari, Tiziana</creatorcontrib><creatorcontrib>Cappelleri, Joseph C</creatorcontrib><creatorcontrib>Camidge, D Ross</creatorcontrib><title>Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>To compare clinical trial results for crizotinib and entrectinib in -positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. We analyzed four phase I-II studies using a simulated treatment comparison (STC). A STC of clinical trial versus real-world evidence compared crizotinib clinical data to real-world outcomes. Adjusted STC found nonsignificant trends favoring crizotinib over entrectinib: objective response rate, risk ratio = 1.04 (95% CI: 0.85-1.28); median duration of response, mean difference = 16.11 months (95% CI: -1.57- 33.69); median progression-free survival, mean difference = 3.99 months (95% CI: -6.27-14.25); 12-month overall survival, risk ratio = 1.01 (95% CI: 0.90-1.12). Nonsignificant differences were observed between the trial end point values and the real-world evidence for crizotinib. Crizotinib and entrectinib have comparable efficacy in -positive non-small-cell lung cancer.</description><subject>Benzamides - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Clinical Trials as Topic</subject><subject>Crizotinib - therapeutic use</subject><subject>Humans</subject><subject>Indazoles - therapeutic use</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-Tyrosine Kinases - genetics</subject><subject>Protein-Tyrosine Kinases - therapeutic use</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Treatment Outcome</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNo9kMtPxCAQh4nRuLp69Go4ekF5FFqOZrM-kk028XFuKAWDoXSFdo0e_Nst2dUTw8w3k18-AC4IvqaUlDe2D4hiShAhmB6AE1IWBaoYJodTXZQSCSGLGThN6R3jomQcH4MZ45RRyvAJ-Flaa_TgtiaYlGBvoY7uux9ccA3cmpjGBE0YYmZyywX4tH4mEG365PIaDFOA1CnvkTbeQz-GN6hV0CbCMbn88dOmVh6q0MJolEefffQtbNWgzsCRVT6Z8_07B693y5fFA1qt7x8XtyukGaMDsi2viKRT7KoRnEldCKqmkVBMMKk0MRxXRnJuLSskrqQRumxpKZqyaKmt2Bxc7e5uYv8xmjTUnUs5rwqmH1NNRVYiMS8nFO1QHfuUorH1JrpOxa-a4DorryfldVZeZ-UTf7k_PTadaf_pP8fsF-qjfTQ</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Tremblay, Gabriel</creator><creator>Groff, Michael</creator><creator>Iadeluca, Laura</creator><creator>Daniele, Patrick</creator><creator>Wilner, Keith</creator><creator>Wiltshire, Robin</creator><creator>Bartolome, Lauren</creator><creator>Usari, Tiziana</creator><creator>Cappelleri, Joseph C</creator><creator>Camidge, D Ross</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0623-3545</orcidid></search><sort><creationdate>20220601</creationdate><title>Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data</title><author>Tremblay, Gabriel ; Groff, Michael ; Iadeluca, Laura ; Daniele, Patrick ; Wilner, Keith ; Wiltshire, Robin ; Bartolome, Lauren ; Usari, Tiziana ; Cappelleri, Joseph C ; Camidge, D Ross</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c332t-fd581923528b6539c462ac336a3639ac1e508e955ff349089e6c7d276b74d2f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Benzamides - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Clinical Trials as Topic</topic><topic>Crizotinib - therapeutic use</topic><topic>Humans</topic><topic>Indazoles - therapeutic use</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-Tyrosine Kinases - genetics</topic><topic>Protein-Tyrosine Kinases - therapeutic use</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tremblay, Gabriel</creatorcontrib><creatorcontrib>Groff, Michael</creatorcontrib><creatorcontrib>Iadeluca, Laura</creatorcontrib><creatorcontrib>Daniele, Patrick</creatorcontrib><creatorcontrib>Wilner, Keith</creatorcontrib><creatorcontrib>Wiltshire, Robin</creatorcontrib><creatorcontrib>Bartolome, Lauren</creatorcontrib><creatorcontrib>Usari, Tiziana</creatorcontrib><creatorcontrib>Cappelleri, Joseph C</creatorcontrib><creatorcontrib>Camidge, D Ross</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tremblay, Gabriel</au><au>Groff, Michael</au><au>Iadeluca, Laura</au><au>Daniele, Patrick</au><au>Wilner, Keith</au><au>Wiltshire, Robin</au><au>Bartolome, Lauren</au><au>Usari, Tiziana</au><au>Cappelleri, Joseph C</au><au>Camidge, D Ross</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>18</volume><issue>17</issue><spage>2063</spage><epage>2074</epage><pages>2063-2074</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>To compare clinical trial results for crizotinib and entrectinib in -positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. We analyzed four phase I-II studies using a simulated treatment comparison (STC). A STC of clinical trial versus real-world evidence compared crizotinib clinical data to real-world outcomes. Adjusted STC found nonsignificant trends favoring crizotinib over entrectinib: objective response rate, risk ratio = 1.04 (95% CI: 0.85-1.28); median duration of response, mean difference = 16.11 months (95% CI: -1.57- 33.69); median progression-free survival, mean difference = 3.99 months (95% CI: -6.27-14.25); 12-month overall survival, risk ratio = 1.01 (95% CI: 0.90-1.12). Nonsignificant differences were observed between the trial end point values and the real-world evidence for crizotinib. Crizotinib and entrectinib have comparable efficacy in -positive non-small-cell lung cancer.</abstract><cop>England</cop><pmid>35232230</pmid><doi>10.2217/fon-2021-1102</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-0623-3545</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1479-6694
ispartof Future oncology (London, England), 2022-06, Vol.18 (17), p.2063-2074
issn 1479-6694
1744-8301
language eng
recordid cdi_proquest_miscellaneous_2635239057
source PubMed Central
subjects Benzamides - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Clinical Trials as Topic
Crizotinib - therapeutic use
Humans
Indazoles - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - genetics
Protein-Tyrosine Kinases - therapeutic use
Proto-Oncogene Proteins - genetics
Treatment Outcome
title Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20crizotinib%20versus%20entrectinib%20in%20ROS1%20-positive%20non-small-cell%20lung%20cancer%20using%20clinical%20and%20real-world%20data&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Tremblay,%20Gabriel&rft.date=2022-06-01&rft.volume=18&rft.issue=17&rft.spage=2063&rft.epage=2074&rft.pages=2063-2074&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2021-1102&rft_dat=%3Cproquest_cross%3E2635239057%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c332t-fd581923528b6539c462ac336a3639ac1e508e955ff349089e6c7d276b74d2f83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2635239057&rft_id=info:pmid/35232230&rfr_iscdi=true